NYSE:BHVN - Biohaven Pharmaceutical Stock Price, News, & Analysis

$40.65
-3.17 (-7.23 %)
(As of 06/19/2019 04:00 PM ET)
Today's Range
$40.24
Now: $40.65
$44.34
50-Day Range
$44.38
MA: $60.55
$67.01
52-Week Range
$29.17
Now: $40.65
$67.86
Volume6.01 million shs
Average Volume673,858 shs
Market Capitalization$1.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.72
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.74 per share

Profitability

Net Income$-240,920,000.00

Miscellaneous

Employees63
Market Cap$1.80 billion
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($1.41) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.50) by $0.09. During the same quarter in the previous year, the company posted ($2.32) earnings per share. View Biohaven Pharmaceutical's Earnings History.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Biohaven Pharmaceutical.

What price target have analysts set for BHVN?

11 equities research analysts have issued 1 year target prices for Biohaven Pharmaceutical's shares. Their predictions range from $50.00 to $100.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $73.20 in the next year. This suggests a possible upside of 80.2% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

What is the consensus analysts' recommendation for Biohaven Pharmaceutical?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

What are Wall Street analysts saying about Biohaven Pharmaceutical stock?

Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (5/9/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Overweight rating and raising our PT on BHVN to $75 from $65. The price target upgrade is a result of recent, but ongoing, due diligence in the space that refines our thinking on the evolving treatment paradigm. As a result, we have recast our model, now based on assumed use in certain target populations that we believe would be most appropriate for oral CGRPs. Namely, this includes the migraine patients contraindicated for triptans and those patients that fail to consistently respond to/tolerate triptans." (2/8/2019)

Has Biohaven Pharmaceutical been receiving favorable news coverage?

News headlines about BHVN stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a news impact score of -1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Biohaven Pharmaceutical.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a increase in short interest in May. As of May 15th, there was short interest totalling 3,790,600 shares, an increase of 8.6% from the April 15th total of 3,489,900 shares. Based on an average daily trading volume, of 608,800 shares, the short-interest ratio is currently 6.2 days. Currently, 10.9% of the company's stock are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include Biopharmx (BPMX), Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Flexion Therapeutics (FLXN), Amicus Therapeutics (FOLD), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD), Anavex Life Sciences (AVXL) and Crispr Therapeutics (CRSP).

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:
  • Dr. Vladimir Coric, CEO & Director (Age 48)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 57)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (4.00%), Janus Henderson Group PLC (2.83%), Eagle Asset Management Inc. (2.22%), Rubric Capital Management LP (1.60%), Emerald Advisers LLC (1.34%) and Vivo Capital LLC (1.14%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Julia P Gregory, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Vivo Capital LLC, FMR LLC, JPMorgan Chase & Co., Rubric Capital Management LP, Candriam Luxembourg S.C.A., Aureus Asset Management LLC and SG Americas Securities LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, John Tilton, Julia P Gregory and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Spark Investment Management LLC, State of New Jersey Common Pension Fund D, C WorldWide Group Holding A S, Atika Capital Management LLC, Pier Capital LLC, ARS Investment Partners LLC and EAM Global Investors LLC. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $40.62.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $1.80 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel